Portage Biotech Inc. (PRTG)

VG — Healthcare Sector
Peers: AMLX  KRTX  BPMC  ARVN  AVTE  ELYM  ANEB  CUE  DBTX  KROS  JANX  FENC  EWTX  HRMY  LCTX  MAIA  ARMP  FREQ  DAWN  ABOS  XFOR  INZY  VECT 

Automate Your Wheel Strategy on PRTG

With Tiblio's Option Bot, you can configure your own wheel strategy including PRTG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PRTG
  • Rev/Share 0.0
  • Book/Share 0.6459
  • PB 6.4498
  • Debt/Equity 0.02
  • CurrentRatio 3.0767
  • ROIC -5.5287

 

  • MktCap 9394466.0
  • FreeCF/Share -9.1022
  • PFCF -0.9592
  • PE -0.134
  • Debt/Assets 0.0103
  • DivYield 0
  • ROE -6.7396

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Portage Biotech Stock Surges As It Prepares For Human Trial
PRTG
Published: April 28, 2025 by: Benzinga
Sentiment: Positive

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human trial preparations are underway.

Read More
image for news Portage Biotech Stock Surges As It Prepares For Human Trial
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
PRTG
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor.

Read More
image for news Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Why Is Portage Biotech Stock Skyrocketing Friday?
PRTG
Published: March 28, 2025 by: Benzinga
Sentiment: Positive

Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.

Read More
image for news Why Is Portage Biotech Stock Skyrocketing Friday?

About Portage Biotech Inc. (PRTG)

  • IPO Date 2002-01-02
  • Website https://www.portagebiotech.com
  • Industry Biotechnology
  • CEO Mr. Alexander Pickett
  • Employees 7
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.